Cyclophilin D induces necrotic core formation by promoting mitochondria-mediated macrophage apoptosis in advanced atherosclerotic lesions
Jun-ichiro Koga,Ryuta Umezu,Tomohiro Shirouzu,Yuki Kondo,Nasanbadrakh Orkhonselenge,Hiromichi Ueno,Shunsuke Katsuki,Tetsuya Matoba,Yosuke Nishimura,Masaharu Kataoka,Koga,J.-i.,Umezu,R.,Shirouzu,T.,Kondo,Y.,Orkhonselenge,N.,Ueno,H.,Katsuki,S.,Matoba,T.,Nishimura,Y.,Kataoka,M.
DOI: https://doi.org/10.1101/2023.09.05.556288
2023-09-07
bioRxiv
Abstract:Background: In advanced atherosclerotic lesions, apoptotic cell death of plaque macrophages results in necrotic core formation and plaque vulnerability. Cyclophilin D (CypD) is a mitochondria-specific cyclophilin involved in the process of cell death after organ ischemia-reperfusion. However, the role of CypD in atherosclerosis, especially in necrotic core formation, is unknown. Methods: To clarify the specific role of CypD, apolipoprotein-E/CypD-double knockout (ApoE -/- CypD -/- ) mice were generated. These mice were fed a high-fat diet containing 0.15% cholesterol for 24 weeks to accelerate atherosclerotic lesion development. Results: The deletion of CypD decreased the necrotic core size, accompanied by a reduction of macrophage apoptosis compared to control ApoE -/- mice. In RAW264.7 cells treated with endoplasmic reticulum stress inducer thapsigargin, the release of cytochrome c to the cytosol was attenuated by siRNA-mediated knockdown of CypD. Ly-6C high inflammatory monocytes in the peripheral blood leukocytes and mRNA expression of Il1b in the aorta were decreased by the deletion of CypD. In contrast, siRNA-mediated knockdown of CypD did not significantly decrease Il1b nor Ccl2 mRNA expression in RAW264.7 cells treated with LPS and IFN-{gamma}, suggesting that inhibition of inflammation in vivo is likely due to decreased cell death in the atherosclerotic lesions rather than a direct action of CypD deletion on the macrophage. Conclusions: This is the first report showing that CypD induces macrophage death and promotes necrotic core formation in advanced atherosclerotic lesions. CypD could be a novel therapeutic target for treating atherosclerotic vascular diseases.